Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies

Histology and Histopathology

Volumn 26, Issue 3, 2011, Pages 409-420

  Yie, Shang Mian ^a   Hu, Zhenbo ^b  

^a CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Diagnosis; HLA G; Immunotherapy; Prognosis; Tumor immune escape; Tumor marker

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA G ANTIGEN; TUMOR MARKER;

BIOSYNTHESIS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-G ANTIGENS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; PROGNOSIS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 79952327972     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Anderson C., Nijagal A. and Kim J. (2006). Molecular markers for gastric adenocarcinoma: an update. Mol. Diagn. Ther. 10, 345-352. (Pubitemid 44927048)
2. Ballimore A. and Golkin A. (2008). Regulatory T cells and tumour immunity: observations in mice and men. Immunology 123, 157-163.
3. Barrier B.F., Kendall B.S., Sharpe-Timms K. and Kost E.R. (2006). Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol. Oncol. 103, 25-30. (Pubitemid 44389864)
4. Bijen C.B., Bantema-Joppe E.J., de Jong R.A., Leffers N., Mourits M.J., Eggink H.F., van der Zee AG., Hollema H., de Bock G.H and Nijman H.W. (2010). The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int. J. Cancer 126, 1417-1427.
5. Brandacher G., Perathoner A., Ladurner R., Schneeberger S., Obrist P., Winkler C., Werner E-R., Werner-Felmayer G., Weiss H.G., G̈bel G., Margreiter R., K̈nigsrainer A., Fuchs D and Amberger A. (2006). Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12, 1144-1151. (Pubitemid 43342502)
6. Cai M.Y., Xu Y.F., Qiu S.J., Ju M.J., Gao Q., Li Y.W., Zhang B.H., Zhou J. and Fan J. (2009). Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin. Cancer Res. 15, 4686-4693.
7. Carosella E.D., Moreau P., Lemaoult J. and Rouas-Freiss N. (2008a). HLA-G: from biology to clinical benefits. Trends Immunol. 29, 125-132.
8. Carosella E.D., Benoit Favier B., Rouas-Freiss N., Moreau P. and Joel LeMaoult J. (2008b). Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 111, 4862-4870.
9. Chen H.X., Lin A., Shen C.J., Zhen R., Chen B.G., Zhang X., Cao F.L., Zhang J.G and Yan W.H. (2010). Up-regulation of human leukocyte antigen-G (HLA-G) expression and its clinical significance in ductal breast cancer. Hum. Immunol. 71, 892-898.
10. Cirulli V., Zalatan J., McMaster M., Prinsen R., Salomon DR., Ricordi C,. Torbett B.E, Meda P. and Crisa L. (2006). The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLAG. Diabetes 55, 1214-1222. (Pubitemid 44195357)
11. Clements C.S., Kjer-Nielsen L., McCluskey J. and Rossjohn J. (2007). Structural studies on HLA-G: implications for ligand and receptor binding. Hum. Immunol. 68, 220-226. (Pubitemid 46497514)
12. Crisa L., McMaster M.T., Ishii J.K., Fisher S.J. and Salomon D.R. (1997). Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J. Exp. Med. 186, 289-298. (Pubitemid 27328029)
13. Curiel T. (2007). Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117, 1167-1174. (Pubitemid 46718401)
14. Dai X.C. and Zhu B.T. (2010). Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: Implications for its biological functions. J. histochem. Cytochem. 58, 17-28.
15. Davidson B., Elstrand M.B., McMaster M.T., Berner A., Kurman R.J., Risberg B., Trope C.G. and Shih IeM. (2005). HLA-G expression in effusions is a possible marker of tumour susceptibility to chemotherapy in ovarian carcinoma. Gynecol. Oncol 96, 42-47. (Pubitemid 39612415)
16. de la Cruz-Merino L., Grande-Pulido E., Albero-Tamarit A and Codes-Manuel de Villena M.E. (2008). Cancer and immune response: old and new evidence for future challenges. Oncologist 13, 1246-1254.
17. Demaria S., Volm M.D., Shapiro R.L., Yee H.T., Oratz R., Formenti S.C., Muggia F. and Symmans W.F. (2001). Development of tumorinfiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin. Cancer Res. 7, 3025-3030. (Pubitemid 32963819)
18. Dong D.D., Yang H., Li K., Xu G., Song L.H., Fan X.L., Jiang X.L and Yie S.M. (2010). Human Leukocyte Antigen-G (HLA-G) expression in cervical lesions: Association with cancer progression, HPV 16/18 infection, and host Iimune response. Reprod. Sci. 17, 718-723.
19. Dunn G.P., Bruce A.T., Ikeda H., Old L.J. and Schreibe R.D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998. (Pubitemid 35363648)
20. Dunn G.P., Old L.J. and Schreiber R.D. (2004). The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360. (Pubitemid 38680426)
21. Erikci A.A., Karagoz B., Ozyurt M., Ozturk A., Kilic S. and Bilgi O. (2009). HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology 14, 101-105.
22. Favier B., LeMaoult J., Rouas-Freiss N., Moreau P., Menier C. and Carosella E.D. (2007). Research on HLA-G: an update. Tissue Antigens 69, 207-211. (Pubitemid 46696937)
23. Fokkema E., Timens W., de Vries E.G., de Jong S., Fidler V., Meijer C. and Groen H.J. (2006).Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung Cancer 52, 241-247.
24. Fons P., Chabot S., Cartwright J.E., Lenfant F., L'Faqihi F., Giustiniani J and Jean-Pascal Herault J.P. (2006).Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 108, 2608-2615.
25. Gagnon A and Ye B. (2008). Discovery and application of protein biomarkers for ovarian cancer. Curr. Opin. Obstet. Gynecol. 20, 9-13.
26. Giannopoulos K., Schmitt M., Kowal M., Własiuk P., Bojarska-Junak A., Rolinski J and Dmoszyńska A. (2008). The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL). Leuk. Res. 32, 1815-1819.
27. Gonzalez-Hernandez A., Lemaoult J., Lopez A., Alegre E., Caumartin J., Le Rond S., Daouya M., Moreau P. and Carosella E.D. (2005). Linking two immuno-suppressive molecules: indoleamine 2,3 dioxygenase can modify HLA-G cell-surface expression. Biol. Reprod. 3, 571-578. (Pubitemid 41170213)
28. Greenberg A.K. and Lee M.S.(2007). Biomarkers for lung cancer: clinical uses. Curr. Opin. Pulm. Med. 13, 249-255. (Pubitemid 46847287)
29. Gros F., Sebti Y., de Guibert S., Branger B., Bernard M., Fauchet R. and Amiot L. (2006). Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 8, 223-230. (Pubitemid 43671238)
30. He X., Dong D.D., Yie S.M., Yang H., Cao M., Ye S.R., Li K., Liu J. and Chen J. (2010). HLA-G expression in human breast cancer: Implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann. Surg. Oncol. 17, 1459-1469.
31. Hofmeister V. and Weiss E.H. (2003). HLA-G modulates immune responses by diverse receptor interactions. Semin. Cancer Biol. 13, 317-323. (Pubitemid 38160930)
32. Hori S., Nomura T. and Sakaguchi S. (2003). Control of regulatory T cell development by the transcription factor FoxP3. Science 299, 1057-1061. (Pubitemid 36222930)
33. Hundt S., Haug U. and Brenner H. (2007). Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol. Biomarkers Prev. 16, 1935-1953. (Pubitemid 47621167)
34. Ino K., Yoshida N., Kajiyama H., Shibata K., Yamamoto E., Kidokoro K., Takahashi N., Terauchi M., Nawa A., Nomura S., Nagasaka T., Takikawa O. and Kikkawa F. (2006). Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer. 95, 1555-1561. (Pubitemid 44863359)
35. Ishigami S., Natsugoe S., Miyazono F., Nakajo A., Tokuda K., Matsumoto M., Okumura H., Douchi T., Hokita S and Aikou T. (2006). HLA-G expression in gastric cancer. Anticancer Res. 26, 2467-2472. (Pubitemid 43980219)
36. Jotwani A.C and Gralow J.R. (2009). Early detection of breast cancer: New biomarker tests on the horizon? Mol. Diagn. Ther. 13, 349-357.
37. Jung Y.W., Kim Y.T., Kim S.W., Kim S., Kim J.H., Cho N.H. and Kim J.W. (2009). Correlation of human leukocyte antigen-G (HLA-G) expression and disease progression in epithelial ovarian cancer. Reprod. Sci. 16, 1103-1111.
38. Kleinberg L., Flørenes V.A., Skrede M., Dong H.P., Nielsen S., McMaster M.T., Nesland J.M., Shih IeM and Davidson B. (2006). Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 449, 31-39. (Pubitemid 43988363)
39. Kondratiev S., Sabo E., Yakirevich E., Lavie O. and Resnick M.B. (2004). Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin. Cancer Res. 10, 4450-4456. (Pubitemid 38878888)
40. Laheru D. and Jafee E. (2007). The cancer handbook. Cancer vaccines. Second Edition. Chichester, UK, Wiley. pp 1268-1274.
41. Le Discorde M., Moreau P., Sabatier P., Legeais J.M. and Carosella E.D. (2003). Expression of HLA-G in human cornea, an immuneprivileged tissue. Hum. Immunol. 64, 1039-1044. (Pubitemid 37413712)
42. Leithauser F., Dhein J., Mechtersheimer G., Koretz K., Bruderlein S., Henne C., Schmidt A., Debatin K.M., Krammer P.H and Moller P. (1993). Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69, 415-429 (Pubitemid 23335841)
43. Leleu X., Le Friec G., Facon T., Amiot L., Fauchet R., Hennache B., Coiteux V., Yakoub-Agha I., Sylvain Dubucquoi S. Avet-Loiseau H., Mathiot C., Bataille R., Jean-Yves Mary J.Y. and on behalf of the Intergroupe Francophone du Myélome. (2005). Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin. Cancer Res. 11, 7297-7303. (Pubitemid 41507687)
44. Li B.L., Lin A., Zhang X.J., Zhang X., Zhang J.G., Wang Q., Zhou W.J., Chen H.X., Wang T.J. and Yan W.H. (2009). Characterization of HLA-G expression in renal cell carcinoma. Tissue Antigens 74, 213-221.
45. Lin A., Yan W.H., Xu H.H., Gan M.F., Cai J.F., Zhu M. and Zhou M.Y. (2007). HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann. Oncol. 18, 1804-1809.
46. Lin A., Chen H.X., Zhu C.C., Zhang X., Xu H.H., Zhang J.G., Wang Q., Zhou W.J and Yan W.H. (2010a). Aberrant human leukocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J. Cell Mol. Med. 14, 2162-2171.
47. Lin A., Zhu C.C., Chen H.X., Chen B.F., Zhang X., Zhang J.G., Wang Q., Zhou W.J., Hu W., Yang H.H., Xu H.H and Yan W.H.(2010b). Clinical relevance and functional implications for human leukocyte antigen-G expression in non-small-cell lung cancer. J. Cell Mol. Med. 14, 2318-2329.
48. Lindaman A., Dowden A. and Zavazava N. (2006). Soluble HLA-G molecules induce apoptosis in natural killer cells. Am. J. Reprod. Immunol. 56, 68-76. (Pubitemid 43871640)
49. Menier C., Saez B., Horejsi V., Martinozzi S., Krawice-Radanne I., Bruel S, Le Danff C., Reboul M., Ivan Hilgert I., Rabreau M, Larrad M.L., Pla M., Carosella E.D. and Rouas-Freiss N. (2003). Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum. Immunol 64, 315-326. (Pubitemid 36255272)
50. Mitsdoerffer M., Schreiner B., Kieseier B.C., Neuhaus O., Dichgans J., Hartung H.P., Weller M. and Wiendl H. (2004). Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-ß in vitro and in vivo: rationale for the therapy of multiple sclerosis. J. Neuroimmunol. 159, 159-164.
51. Morandi F., Levreri I., Bocca P., Galleni B., Raffaghello L., Ferrone S., Prigione I. and Pistoia V. (2007). Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 67, 6433-6441. (Pubitemid 47037528)
52. Munakata S., Watanabe O., Ohashi K. and Morino H. (2005). Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance. Am. J. Clin. Pathol. 123, 879-885. (Pubitemid 40740686)
53. Nadal C., Maurel J., Gallego R., Castells A., Longarón R., Marmol M., Sanz S., Molina R., Martin-Richard M. and Gascón P.(2005). FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin. Cancer Res. 11, 4770-4774. (Pubitemid 41557197)
54. Naji A., Durrbach A., Carosella E.I.D. and Rouas-Freiss N. (2007). Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. Hum. Immunol. 68, 233-239. (Pubitemid 46497518)
55. Neuber K. and Eidam N. (2006). Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival. Onkologie 29, 361-365. (Pubitemid 44370804)
56. Nuckel H., Rebmann V., Durig J., Duhrsen U and Grosse-Wilde H. (2005). HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105, 1694-1698. (Pubitemid 40223692)
57. Pan K., Wang H., Chen M.S., Zhang H.K., Weng D.S., Zhou J., Huang W., Li J.J., Song H.F and Xia J.C. (2008). Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J. Cancer. Res. Clin. Oncol. 134, 1247-1253.
58. Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Beatrice Riteau B., Le Gal F.A., Avril M.F., Dausset J., Guillet J.G. and Carosella E.D. (1998). HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA 95, 4510-4515. (Pubitemid 28207943)
59. Perez-Chacon G., Rosado S., Rebolleda N., Losada-Fernandez I., Vargas J.A., Morado M., Jorda J. and Perez-Aciego P. (2009). Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. Int. J. Lab. Hematol. 31, 327-37.
60. Perkins N.J., Schisterman E.F. and Vexler A. (2009). Generalized ROC curve inference for a biomarker subject to a limit of detection and masurement error. Stat Med. 28, 1841-1860.
61. Piras F., Colombari R., Minerba L., Murtas D., Floris C., Maxia C., Corbu A., Perra M.T. and Sirigu P. (2005). The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104, 1246-1254. (Pubitemid 41278960)
62. Pistoia V., Morandi F.,Wang X. and Ferrone S. (2007). Soluble HLA-G: Are they clinically relevant? Semin. Cancer Biol. 17, 469-79. (Pubitemid 350064562)
63. Poláková K., Bandzuchová E., Kuba D. and Russ G. (2009). Demethylating agent 5-aza-2'-deoxycytidine activates HLA-G expression in human leukemia cell lines. Leuk. Res. 33, 518-24.
64. Reimer T., Koczan D., Müller H., Friese K., Thiesen H.J. and Gerber B. (2002).Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer. Breast Cancer Res. 4, R9.
65. Riesenberg R., Weiler C., Spring O., Eder M., Buchner A., Popp T., Castro M., Kammerer R., Takikawa O., Hatz R.A., Stief C.G., Hofstetter A. and Zimmermann W. (2007). Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin. Cancer Res. 13, 6993-7002. (Pubitemid 350276880)
66. Sandel M.H., Dadabayev A.R., Menon A.G., Morreau H., Melief C.J.M., Offringa R., van der Burg S.H., Janssen-van Rhijn C.M., Ensink N.G., Tollenaar R.A.E.M., van deVelde C.J.H. and Kuppen P.J.K. (2005). Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: Role of maturation status and intratumoral localization. Clin. Cancer Res. 11, 2576-2582. (Pubitemid 40569456)
67. Schumacher K., Haensch W., R̈efzaad C. and Schlag P.M. (2001). Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res. 61, 3932-3936. (Pubitemid 32720953)
68. Schütt P., Schütt B., Switala M., Bauer S., Stamatis G., Opalka B., Eberhardt W., Schuler M., Horn P.A and Rebmann V. (2010). Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum. Immunol. 2010 71, 489-495.
69. Sebti Y., Le Maux A., Gros F., De Guibert S., Pangault C., Rouas-Freiss N., Bernard M and Amiot L. (2007). Expression of functional soluble human leukocyte antigen-G molecules in lymphoproliferative disorders. Br. J. Haematol 138, 202-212. (Pubitemid 46976330)
70. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., Rouas-Freiss N., Carosella E.D and Deschaseaux F. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 26, 212-222.
71. Selmani Z., Naji A., Gaiffe E., Obert L., Tiberghien P., Rouas-Freiss N., Carosella E.D. and Deschaseaux F. (2009). HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 87 (Suppl), S62-66.
72. Shevach E.M. (2002). CD4+ CD25+ suppressor T cells: More questions than answers. Nat. Rev. Immunol. 2, 389-400. (Pubitemid 37328746)
73. Singer G., Rebmann V., Chen Y.C., Liu H.T., Ali S.Z., Beinsberg J., McMaster M.T., Pfeiffer K., Chan D.W., Wardelmann E., Grosse-Wilde H., Cheng C.C., Kurman R.J. and Shih IeM. (2003).HLA-G is a potential tumor marker in malignant ascites. Clin. Cancer Res. 9, 4460-4464. (Pubitemid 37248404)
74. Shih I.M. (2007). Application of HLA-G Expression in the Diagnosis of Human Cancer. Hum. Immunol. 68, 272-276.
75. Shimizu M., Kondo M., Ito Y., Kume H., Suzuki R and Yamaki K. (2005). Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Cancer Detect. Prev. 29, 175-180.
76. Strege R.J., Godt C., Stark A.M., Hugo H.H. and Mehdorn HM. (2004). Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas. J. Neurooncol. 67, 29-39. (Pubitemid 38418246)
77. Swann J.B and Smyth M.J. (2007). Immune surveillance of tumors. J. Clin. Invest. 117, 1137-1146. (Pubitemid 46718398)
78. Urosevic M. and Dummer R. (2008). Human leukocyte antigen-G and cancer immunoediting. Cancer Res. 68, 627-630. (Pubitemid 351206734)
79. Ugurel S., Rappl G., Tilgen W. and Reinhold U. (2001). Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin. Cancer Res. 7, 1282-1286. (Pubitemid 32708681)
80. Ugurel S., Rebmann V., Ferrone S., Tilgen W., Grosse-Wilde H. and Reinhold U. (2001). Soluble human leukocyte antigen-G serum levelis elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 92, 369-376. (Pubitemid 32664444)
81. Urosevic M., Kurrer M.O., Kamarashev J., Mueller B., Weder W., Burg G., Stahel R.A., Dummer R. and Trojan A. (2001).Human leukocyte antigen G up-regulation in lung cancer associates with high-grade, human histology, leukocyte antigen class I loss and interleukin-10 production. Am. J. Pathol. 159, 817-824. (Pubitemid 32847172)
82. Weinlich G., Murr C., Richardsen L., Winkler C. and Fuchs D. (2007). Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology. 214, 8-14. (Pubitemid 46032994)
83. Yan W.H, Lin A., Chen B.G., Luo W.D., Dai M.Z., Chen X.J., Xu H.H. and Li B.L. (2008). Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J. Cell Mol. Med. 12, 889-898. (Pubitemid 351718068)
84. Ye S.R., Yang H., Li K., Dong D.D., Lin X.M. and Yie S.M. (2007). Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod. Pathol. 20, 375-383. (Pubitemid 46348337)
85. Yie S.M., Yang H., Ye S.R., Li K., Dong D.D. and Lin X.M. (2007a). Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann. Surg. Oncol. 14, 2721-2729. (Pubitemid 47460633)
86. Yie S.M., Yang H., Ye S.R., Li K., Dong D.D. and Lin X.M. (2007b). Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 58, 267-274. (Pubitemid 47516690)
87. Yie S.M., Yang H., Ye S.R., Li K., Dong D.D. and Lin X.M. (2007c). Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am. J. Clin. Pathol. 128, 1002-1009.
88. Yu P. and Fu Y.X. (2006). Tumor-infiltrating T lymphocytes: friends or foes? Lab. Invest. 86, 231-245. (Pubitemid 43276955)
89. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani, G., Makrigiannakis, A., Gray H., Schlienger K., Liebman, M.N., Rubin S.C., and Coukos G. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213. (Pubitemid 36077915)
90. Zhu C.B., Wang C.X., Zhang X., Zhang J. and Li W. (2010). Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int. J. Cancer (Epub ahead of print)
91. Zou W. (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307.